MARKET

ALKS

ALKS

Alkermes Plc
NASDAQ
42.77
+2.83
+7.07%
Opening 11:29 05/29 EDT
OPEN
40.00
PREV CLOSE
39.94
HIGH
42.78
LOW
39.64
VOLUME
1.41M
TURNOVER
--
52 WEEK HIGH
42.78
52 WEEK LOW
25.17
MARKET CAP
7.13B
P/E (TTM)
47.55
1D
5D
1M
3M
1Y
5Y
1D
Assessing Alkermes (ALKS) Valuation After New Clinical And Real World Data On Key Psychiatry Drugs
Simply Wall St · 17h ago
Needham Reiterates Buy Rating on Alkermes as Preclinical ALKS 7290 Data Support Unchanged $50 Price Target
TipRanks · 17h ago
Analysts’ Top Healthcare Picks: Gilead Sciences (GILD), Alkermes (ALKS)
TipRanks · 3d ago
Alkermes presents Phase 2 Vibrance-1 data on alixorexton in narcolepsy type 1 at ASCP meeting
PUBT · 3d ago
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
Barchart · 3d ago
Weekly Report: what happened at ALKS last week (0518-0522)?
Weekly Report · 4d ago
Alkermes presents real-world study comparing Lybalvi versus olanzapine adherence, relapse proxies
PUBT · 05/21 11:01
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
Barchart · 05/21 06:00
More
About ALKS
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.

Webull offers Alkermes Plc stock information, including NASDAQ: ALKS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALKS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALKS stock methods without spending real money on the virtual paper trading platform.